stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Gross margin
GSK PLC Sponsored ADR's gross margin over the twelve months to 30 September 2026 was 72.6%, up 0.2 percentage points from fiscal 2025 (72.4%). Over the past ten years it has ranged from 63.0% (fiscal 2015) to 72.4% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 72.4% | 1.24 |
| FY2024 | 71.2% | (0.60) |
| FY2023 | 71.8% | 4.34 |
| FY2022 | 67.4% | 1.43 |
| FY2021 | 66.0% | 0.31 |
| FY2020 | 65.7% | 0.83 |
| FY2019 | 64.9% | (1.92) |
| FY2018 | 66.8% | 1.03 |
| FY2017 | 65.7% | (0.95) |
| FY2016 | 66.7% | 3.70 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 73.1% | 0.06 |
| Jun 2026 | 73.1% | (2.37) |
| Mar 2026 | 75.4% | 6.19 |
| Dec 2025 | 69.2% | (4.35) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| BIIB Biogen Inc. compare | 74.0% |
| SNY Sanofi compare | 73.4% |
| PFE Pfizer Inc. compare | 73.4% |
| GSK GSK PLC Sponsored ADR | 72.6% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement